Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 0.59 |
| ▸ | HTR2A | P28223 | 19/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 18/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7560029 | 0.83 | SLC6A4 (0.59) | SLC6A4HTR2AKCNH2HRH3 | |
| SCHEMBL6151377 | 0.77 | HTR2A (0.65) | SLC6A4HTR2AKCNH2 | |
| SCHEMBL6151683 | 0.77 | HTR2A (0.65) | SLC6A4HTR2AKCNH2 | |
| SCHEMBL6152387 | 0.76 | SLC6A4 (0.58) | SLC6A4HTR2AKCNH2HRH3 | |
| Hydrochloric Acid SCHEMBL7228120 | 0.76 | HTR2A (0.64) | SLC6A4HTR2AKCNH2 | |
| SCHEMBL3947165 | 0.74 | SLC6A4 (0.68) | SLC6A4HTR2AKCNH2HRH3 | |
| SCHEMBL6153640 | 0.74 | SLC6A4 (0.56) | SLC6A4HTR2AKCNH2HRH3 | |
| SCHEMBL5837833 | 0.74 | SLC6A4 (1.00) | SLC6A4HTR2AKCNH2 | |
| SCHEMBL6152014 | 0.74 | SLC6A4 (0.58) | SLC6A4HTR2AKCNH2HRH3 | |
| SCHEMBL4019960 | 0.74 | SLC6A4 (0.68) | SLC6A4HTR2AKCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030055038-A1 | Novel biaryl ether derivatives useful as monoamine reuptake inhibitors | PFIZER INC. | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055038-A1 | Novel biaryl ether derivatives useful as monoamine reuptake inhibitors | SLC6A2, SLC6A3, SLC18A2 | SLC6A4 6/4885HTR2A 24/4885KCNH2 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.